Evidence map›Paper›PMID 40139128›Full record

Observational studyJournal of neuroimmunology2025

Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis.

Burcu Zeydan, Nur Neyal, Nabeela Nathoo, Manu Rangachari, Elizabeth J Atkinson, Jiye Son, Brittani L Conway, W Oliver Tobin, B Mark Keegan, Brian G Weinshenker and 3 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of neuroimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Burcu ZeydanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA; Women's Health Research Center, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address: zeydan.burcu@mayo.edu.
Nur NeyalDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Nabeela NathooDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA; Department of Neurology, University of Alberta, Edmonton, AB, Canada.
Manu RangachariCentre de recherche du CHU de Québec, axe Neurosciences, Université Laval, Québec City, QC, Canada; Faculté de médecine, Université Laval, Québec City, QC, Canada.
Elizabeth J AtkinsonQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Jiye SonDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Brittani L ConwayDepartment of Neurology, University of Minnesota, Minneapolis, MN, USA.
W Oliver TobinDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
B Mark KeeganDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Brian G WeinshenkerDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Neurology, University of Virginia, VA, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, MN, USA; Women's Health Research Center, Mayo Clinic, Rochester, MN, USA.
Jiwon OhDepartment of Neurology, University of Toronto, Toronto, ON, Canada.
Orhun H KantarciDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.

Funding

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's DiseaseU54AG044170 · NIA · MAYO CLINIC ROCHESTER · PI KAPOOR, EKTA · 2018 to 2022
$7.7M
Mayo Clinic Building Interdisciplinary Research Careers in Women’s HealthK12AR084222 · NIAMS · MAYO CLINIC ROCHESTER · PI KANTARCI, KEJAL · 2023 to 2024
$733k
NIAMS NIH HHS K12 AR084222NIA NIH HHS U54 AG044170
6 · The paper itself

Abstract

backgroundAnti-inflammatory properties of androgens were assessed in animal models, but only several clinical studies investigated the effects of androgen on multiple sclerosis (MS). Inflammatory activity in MS often attenuates with aging, and androgen modifying therapies (AMT), which mimic decreased androgen levels, are frequently used in older men. We aimed to investigate if the number of disease activity events would increase in older (≥55 years) male persons with MS (MPwMS) who are on AMT.

methodsMPwMS with AMT initiation ≥55 years (AMT; n = 60) and without AMT history (no-AMT; n = 80) were included from a clinical-based observational study cohort. Clinical (relapses), Radiological (new lesions), and Disease (relapses and/or new lesions) activity events were evaluated before and after the age at AMT initiation in AMT and no-AMT groups.

resultsAge at MS onset, progressive MS rate and treatment frequencies were similar between the groups. When events before and after the age at AMT initiation (mean = 65.0 ± 7.0 years) were compared, there was a drop in the percentage of individuals with Clinical (38.5 % vs. 10 %), Radiological (46.2 % vs. 40 %) and Disease (62.8 % vs. 40 %) activity events in the no-AMT group. In the AMT group, the percentage of individuals with Clinical activity events was not as dramatically decreased (33.3 % vs. 22.2 %), Radiological activity events was increased (35.2 % vs. 46.7 %), and Disease activity events was sustained (51.9 % vs. 51.1 %). The probability of Disease activity was higher in the AMT group at 3 years of AMT initiation (40 % vs. 29 %) compared to the no-AMT group matched for disease duration, but the difference was not significant (p = 0.582).

conclusionsRather than the expected decrease in disease activity with age, MPwMS receiving AMT experienced sustained or increased disease activity, particularly at >65 years. Close clinical monitoring of MPwMS starting on these medications is necessary.

Indexed as

AndrogensMultiple SclerosisAgedCohort StudiesDisease ProgressionHumansMaleMiddle AgedAndrogens5α-reductase inhibitorsAgeAndrogenDisease activityMenMultiple sclerosisSex differences

Identifiers

PMID40139128
PMCPMC12048229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.